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Abstract The envelope glycoproteins of HIV are required for 
viral infectivity. Proteolysis of the precursor envelope glycopro- 
tein gpl60 results in the formation of gpl20 and gp41. Cleavage 
occurs after the sequence Arg-Glu-Lys-Arg. This sequence is 
expected to be a substrate for the cellular protease furin. We 
examined whether furin is responsible for cleavage of gpl60 by 
using a furin-deficient CHO cell line and the same cell line trans- 
fected with furin cDNA, Data obtained from viral transmission 
assays suggested that furin increased viral infectivity but was not 
essential for the maturation of gpl60, implying that other propro- 
tein processing enzymes also recognize this putative furin cleav- 
age site. 
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1. Introduction 
Human immunodeficiency virus type I (HIV-I) is the etiol- 
ogical agent of the acquired immunodeficiency syndrome [1,2]. 
The envelope glycoproteins of HIV are required to initiate the 
infection of human CD4+ cells by a high-affinity interaction 
between the viral envelope glycoprotein gpl20 and the CD4 
molecule on the T cell surface [1-5]. Cleavage of the HIV 
precursor envelope gpl60 to form a large external glycoprotein 
(gpl20) and a small transmembrane protein (gp41) occurs 
within the host cells in the rough endoplasmic reticulum-Golgi 
complex [6,7]. The endoproteolytic cleavage site of gpl60 has 
been determined to be the amino acid sequence Arg-Glu-Lys- 
Arg TM [8]. Site-directed mutagenesis of Arg 5H blocks the cleav- 
age of gp160 as well as viral infectivity [9,10]. Several mammal- 
ian proprotein convertases that share structural and functional 
similarity with the yeast convertase Kex2 have been identified. 
One of these is furin, a calcium-dependent serine endoprotease 
that cleaves precursor proteins after the minimal consensus 
sequence Arg-X-X-Arg [11,12]. Early reports showed that furin 
cleaves the influenza virus hemagglutinin precursor and 
Newcastle disease virus glycoprotein [13,14]. Other proproteins 
requiring cleavage by furin include pro-yon Willebrand factor 
[15], Pseudomonas exotoxin A (PE) [ 16], diphtheria toxin [17,18] 
and the protective antigen of anthrax toxin [19]. 
Hallenberger et al. reported that decanoyl-Arg-Glu-Lys- 
Arg-chloromethylketone, shown in vitro to inhibit furin, 
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greatly reduces the cleavage of HIV gpl60 and consequently 
the infectivity of the virus [20]. However, it should be noted that 
this inhibitor would be expected to inhibit other proteases that 
cleave at Arg or Lys, and therefore cannot be considered a
completely specific furin inhibitor. Anderson et al. [12] demon- 
strated inhibition of HIV gpl60-dependent membrane fusion 
by a furin-directed ~l-antitrypsin variant having the sequence 
Arg-Ile-Pro-Arg 358 at the active site. However, it recently was 
reported that in human T lymphocytes an endopeptidase differ- 
ing from furin in either ion dependence or pH optimum appears 
to be able to process HIV gpl60 [21]. Therefore, it has been 
uncertain whether furin is the only enzyme involved in the 
cleavage of gpl60. 
In this study, we provide evidence that furin contributes to, 
but is not essential for, HIV gpl60 maturation by using furin- 
deficient CHO cells and the same cells bearing an exogenous 
furin cDNA expression construct. Co-cultivation of HIV gener- 
ated from these two types of cells with human T lymphocytes 
suggested that furin and other endopeptidases may each proc- 
ess the viral envelope protein. 
2. Materials and methods 
2.1. Cell culture 
CHO cells and H9 T cells were cultivated in0~-MEM medium supple- 
mented with 5% serum and RPMI 1640 medium with 10% serum, 
respectively, at37°C with 5% CO2. CHO transfectant cells were main- 
tained in the same condition except G418 was added to the medium at 
a final concentration f 200/lg/ml. 
2.2. TransJection of a mouse furin cDNA construct and selection of 
transfeetants 
pAGEFur DNA (2 pg), a mouse furin cDNA expression construct 
containing a neo gene [22], (a generous gift of Dr. K. Nakayama, U of 
Tsukuba, Japan), was transfected into furin-deficient CHO (FDll) 
cells (1 × 105) using Lipofectamine (BRL). The transfected cells were 
diluted into 100-mm dishes 48 h post-transfection and G418 was added 
to the medium at a final concentration f 400 pg/ml. Two weeks later 
clones were selected, expanded and tested for sensitivity to PE by MTT 
assay. The PE-sensitive cells were further analyzed by reverse transcrip- 
tion coupled polymerase chain reaction (RT-PCR) and used in later 
experiments involving HIV. 
2.3. Reverse transcription coupled polymerase chain reaction 
(RT-PCR) assay 
Total RNA from FD11 and FDI l+furin cells was prepared with a 
RNA isolation kit (Promega). Plus and minus primers matched to the 
mouse furin cDNA gene from nt 2132 to 2167 and nt 2858 to 2887 [22], 
respectively, were synthesized on a DNA synthesizer (Applied Biosys- 
terns). A pair of primers corresponding to the mouse fl-actin gene from 
nt 321 to 346 and from nt 735 to 760 was also prepared [23]. Furin and 
fl-actin cDNA were made with a primer extension kit (Promega) follow- 
ing the manufacturer's protocol. Half of the reaction was used as DNA 
template in PCR which was carried out for 30 cycles at 94°C for 30 s, 
55°C for 2 min, and 72°C for 2 min. 
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2.4. Cocultivation and HIV p24 assay 
FD11 and FD11 + furin cells (1 x 106) were seeded in T75 flasks. The 
next day cell culture medium was removed and the flasks were washed 
with serum-free ~-MEM medium. A mixture of 5/zg of pHXB2gpt 
DNA [24] containing biologically active H1V-I genome (generous gift 
from Dr. Robert C. Gallo, NCI, NIH), 10pl of Lipofectamine and 5 ml 
of serum-free medium was prepared and added to each flask. Five hours 
later 5 ml of medium containing 10% serum were transferred to each 
flask. Two days later, 3 x 10 6 H9 cells were added to the each flask for 
co-cultivation. The supernatant medium was collected and the p24 
concentration was determined by an ELISA method performed by 
Advanced BioScience Laboratories. 
3. Results and discussion 
CHO FDl l  is a furin-deficient cell line generated in this 
laboratory by ethyl methane sulfonate (EMS) mutagenesis of 
CHO cells [19,25]. This cell line is resistant to PE because 
intracellular cleavage of the toxin by furin is required for 
translocation to the cytosol. Cell fusion experiments howed 
that this cell line fails to complement the mutation in CHO 
RPE.40, a previously described furin-deficient line [26], indicat- 
ing that both the FDI  1 and RPE.40 lines are mutated in the 
same gene (personal communication of Thomas and Joan 
Moehring, Univ. of Vermont). 
To directly assess the role of furin in processing of gp 160, we 
transfected CHO FDl l  cells with pAGEFur.  A number of 
cloned G418-resistant transfectants were assayed for sensitivity 
to PE. As expected, about 40% of the clones tested regained 
sensitivity to the toxin, suggesting that active furin was present 
in those cells. One of those clones, designated FDI  1 + furin, 
was shown to be sensitive to PE in a cytotoxicity assay (Fig. 1) 
and was used in the following cocultivation assay. To confirm 
that FD11 + furin cells contained the mouse furin gene, RT- 
PCR was performed. PCR results showed that mouse furin 
mRNA was present in FD11 + furin cells but not in FD11 cells, 
consistent with the results of toxin sensitivity assay of those two 
cell lines (Fig. 2). 
Prior work in which the cleavage site in gpl60 was mutagen- 
ized )roved that infection of target cells by HIV absolutely 
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Fig. I. Sensitivity of FDl l  and FDl l  + furin cells to PE. FDl l  and 
FD11 + furin cells (0.2 ml of 1 x 10S/ml) were transferred to wells of a 
96-well plate one day before the assay. PE at different concentration 
was incubated with the cells for 36 h at 37°C. Cell viability was meas- 
ured by adding (3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium 
bromide; Sigma) to a final concentration f0.4 mg/ml for 1 h at 37°C. 
The As40 of dissolved pigment was determined using a microplate 
reader. The data are presented as percentage of absorbance in the 
absence of the toxin. 
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Fig. 2. RT-PCR of the mouse furin gene and the control fl-actin gene. 
RNA prepared from FD11 and FD11 + furin cells was annealed with 
minus strand primers of either the mouse furin gene or the fl-actin gene 
at 65°C for 20 min and cooled to room temperature, cDNA synthesis 
was performed in a 20 pl volume using a primer extension kit at 42°C 
for 30 min and 10 pl of each cDNA reaction were used as templates in
the PCR. The PCR products were analyzed on a 1% agarose gel and 
stained with ethidium bromide. Samples are thefl-actin DNA generated 
from RNA from either FDl l  (lane 1) or from FDII + furin (lane 2) 
cells; 100 bp DNA marker (lane 3); a positive control using mouse furin 
DNA plasmid as a template (lane 4). The mouse furin band marked to 
the right of the gel was absent in FD11 cells (lane 5) but present in 
FD11 + furin cells (lane 6). 
requires processed gpl20 and gp41 and that virus packaged 
with uncleaved gpl60 is devoid of fusogenic activity [9]. To 
examine if H1V generated from FDI  1 cells would be less infec- 
tive for human T cells than virus produced from FD11 + furin 
cells, the plasmid pHXB2gpt was transfected into these two cell 
types and H9 cells were added 2 days later. HIV replication in 
each cell mixture was measured by the p24 antigen concentra- 
tion. The result indicated that p24 was present in both media 
but the concentration was higher in the medium from 
FDI 1 + furin cells than in the medium with FDI  1 cells (Fig. 
3). In a separate xperiment, HIV replication after co-cultiva- 
tion was determined by assaying reverse transcriptase activity. 
Higher activity was found in the samples from FDI  1 + furin 
cells than from FD11 cells (data not shown). These results show 
that furin is a major protease involved in the processing of 
gpl60. However, after incubation for 16 days, the p24 concen- 
tration in the FD11 cell co-cultivation reached a level equiva- 
lent to that present in the FD l l  + furin cell co-cultivation. 
These virus transmission assays suggest hat even in the cells 
without furin, infectious and cytopathic HIV virions were gen- 
erated. The reduced, but not abolished, p24 concentration in 
the FD l l  cell cocultivation medium indicated that other pro- 
tease(s) in addition to furin can cleave at the viral envelope 
cleavage site. 
Several members of the furin family of processing endopro- 
teases are found in many tissues of mice and humans. PC1 was 
shown to possess endoproteolytic activity with specificity for 
cleavage sites that consist of paired basic amino acid residues 
[27]. Decroly et al. reported that PC1 and furin can cleave 
gp160 in cell-free system [28]. PACE4, like furin, is widespread 
in many cell types and therefore is anothercandidate protease 
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Fig. 3. Measurement of p24 concentration from the cell mixture of 
transfected CHO cells and H9 cells. FD11 and FDI 1 + furin cells were 
transfected with pHXB2gpt DNA using lipofectamine. Two days later, 
H9 cells were added to the each flask for co-cultivation. The superna- 
tant medium was collected after further incubation for the time indi- 
cated. The p24 concentration was determined by an ELISA method. 
that may be involved in cleavage of gpl60 because it has a 
substrate specificity that is similar to that of furin [27]. 
The experiments described here depend on the transcription 
and translation of HIV-I proteins in hamster cells. Previous 
workers have presented data suggesting that rodent cells do not 
support efficient replication of HIV-1 [29,30], presumably due 
to the absence of cellular cofactors needed for the activity of 
Rev and Tat [31]. However, the results shown here indicated 
that at least some gpl60 is produced, processed to gpl20 and 
gp41, and inserted in the CHO cell plasma membrane. Our 
results do not show that infective HIV-1 particles are produced, 
because the transfer of the HIV-1 genome to the T cells added 
subsequently may have occurred by fusion with CHO cells 
having surface-expressed gpl20 and gp41. However, even in 
this case, infection of the T cells will depend on proteolytic 
processing of gpl60. 
The present study shows that furin plays a role in processing 
gpl60 in CHO cells, but that other proteases can cleave gpl60 
when furin is not present. Our results are consistent with the 
observations of Ohnishi et al. [32], who showed that LoVo cells, 
in which furin is inactivated by a frameshift mutation in the 
homoB region, function normally with respect o gpl60 proc- 
essing and virus production. In addition, the evidence presented 
here mimics results seen with several bacterial toxins that are 
activated by cleavage at sites containing multiple basic residues 
[19]. In those cases also, other proteases can replace furin when 
it is absent or inhibited. 
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